Rua Life Sciences Plc, together with its subsidiaries, provides polymers, services, and products to the medical device industry in Europe, the United States, and internationally. More Details
Exceptional growth potential with flawless balance sheet.
Share Price & News
How has Rua Life Sciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: RUA is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: RUA's weekly volatility (8%) has been stable over the past year.
7 Day Return
GB Medical Equipment
1 Year Return
GB Medical Equipment
Return vs Industry: RUA exceeded the UK Medical Equipment industry which returned -11.7% over the past year.
Return vs Market: RUA exceeded the UK Market which returned -10% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Rua Life Sciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StWe're Not Worried About Rua Life Sciences' (LON:RUA) Cash Burn
2 months ago | Simply Wall StRua Life Sciences Plc's (LON:RUA) Profit Outlook
6 months ago | Simply Wall StInvestors Who Bought AorTech International (LON:AOR) Shares Three Years Ago Are Now Up 567%
Is Rua Life Sciences undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate RUA's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate RUA's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: RUA is unprofitable, so we can't compare its PE Ratio to the GB Medical Equipment industry average.
PE vs Market: RUA is unprofitable, so we can't compare its PE Ratio to the UK market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate RUA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: RUA is overvalued based on its PB Ratio (10.3x) compared to the GB Medical Equipment industry average (3.5x).
How is Rua Life Sciences forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RUA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.2%).
Earnings vs Market: RUA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: RUA's is expected to become profitable in the next 3 years.
Revenue vs Market: RUA's revenue (60.6% per year) is forecast to grow faster than the UK market (6.7% per year).
High Growth Revenue: RUA's revenue (60.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RUA's Return on Equity is forecast to be high in 3 years time (22%)
How has Rua Life Sciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RUA is currently unprofitable.
Growing Profit Margin: RUA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: RUA is unprofitable, and losses have increased over the past 5 years at a rate of 18.1% per year.
Accelerating Growth: Unable to compare RUA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RUA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-36.8%).
Return on Equity
High ROE: RUA has a negative Return on Equity (-35.87%), as it is currently unprofitable.
How is Rua Life Sciences's financial position?
Financial Position Analysis
Short Term Liabilities: RUA's short term assets (£2.2M) exceed its short term liabilities (£219.0K).
Long Term Liabilities: RUA has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: RUA is debt free.
Reducing Debt: RUA has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RUA has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: RUA has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 2.7% each year
What is Rua Life Sciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RUA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RUA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RUA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RUA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of RUA's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
David Richmond (57 yo)
Mr. David Muir Richmond serves as Chief Executive Officer at Rua Life Sciences Plc since April 1, 2020 and serves as its Director. Mr. Richmond founded Culzean Medical Devices Ltd.,(also known as RUA Medi...
|Executive Chairman & Finance Director||8.33yrs||UK£246.76k||3.1% |
|CEO & Director||0.58yr||UK£34.54k||9.38% |
|Director of Clinical Marketing & Executive Director||4.08yrs||UK£77.73k||0.11% |
|Independent Non-Executive Director||15yrs||UK£30.00k||3.92% |
|Independent Non-Executive Director||2.42yrs||UK£35.48k||no data|
|Independent Non-Executive Director||2.42yrs||UK£34.54k||0.10% |
Experienced Board: RUA's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.3%.
Rua Life Sciences Plc's company bio, employee growth, exchange listings and data sources
- Name: Rua Life Sciences Plc
- Ticker: RUA
- Exchange: AIM
- Founded: 1996
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: UK£26.983m
- Shares outstanding: 16.35m
- Website: https://www.rualifesciences.com
Number of Employees
- Rua Life Sciences Plc
- 2 Drummond Crescent
- KA11 5AN
- United Kingdom
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|RUA||AIM (London Stock Exchange AIM Market)||Yes||Ordinary Shares||GB||GBP||Feb 1997|
|AOHA||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Feb 1997|
Rua Life Sciences Plc, together with its subsidiaries, provides polymers, services, and products to the medical device industry in Europe, the United States, and internationally. The company operates as a ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/11/26 19:09|
|End of Day Share Price||2020/11/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.